Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Yi-Zhuo Zhao"'
2
The role of astragaloside IV in extracellular matrix remodeling in fibrotic heart disease: Regulation of TRPM7-dependent macrophage function
Autor: Yi-Zhuo Zhao, Ying Xu, Kai Feng, Xue-Ting Fan, Yun-Tian Ma, Hui-Ying Yan, Qian-Ru Liu, Yi-Qun Tang
Background: Astragaloside IV (ASG), the main active constituent of Astragalus membranaceus, exerts protective effects against several diseases associated with myocardial fibrosis, while no data suggest its role on macrophages in the process of myocar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47a605a984cbf3dc01320b931e7e8e36
https://doi.org/10.21203/rs.3.rs-2825333/v1
Zobrazit plný text záznamu
6
The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China
Autor: You-ru, Liu, Wei, Zhu, Jian-liang, Zhang, Jia-qi, Huang, Yi-zhuo, Zhao, Wei, Zhang, Bao-hui, Han, Yi-hong, Yao, Li-yan, Jiang, Shan-Qun, Li
Publikováno v: The clinical respiratory journal. 8(2)
Sunitinib is an oral multitargeted tyrosine kinase inhibitor (TKI) exhibiting antiagiogenic and antitumor effects.To evaluate the efficacy and potential toxicity of sunitinib therapy in advanced non-small cell lung cancer (NSCLC) patients in China.Fr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4164fcbfde7f3c5e0efcc776a0dcb7b1
https://pubmed.ncbi.nlm.nih.gov/24118906
Zobrazit plný text záznamu
7
[A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)]
Autor: Bao-hui, Han, Qing-yu, Xiu, Hui-min, Wang, Jie, Shen, Ai-qin, Gu, Yi, Luo, Chun-xue, Bai, Shu-liang, Guo, Wen-chao, Liu, Zhi-xiang, Zhuang, Yang, Zhang, Yi-zhuo, Zhao, Li-yan, Jiang, Chun-lei, Shi, Bo, Jin, Jian-ying, Zhou, Xian-qiao, Jin
Publikováno v: Zhonghua zhong liu za zhi [Chinese journal of oncology]. 33(11)
To analyze the efficacy and quality of life and safety for paclitaxel and carboplatin (TC) and TC combined with endostar in the treatment of advanced non-small cell lung cancer (NSCLC).This is a prospective, multicenter, randomized, double-blind, pla
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4cf2173f4709bf2c547e65907e9eab88
https://pubmed.ncbi.nlm.nih.gov/22335953
Zobrazit plný text záznamu
8
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer
Autor: Shu-liang Guo, Chunxue Bai, Jie Shen, Yi-zhuo Zhao, Baohui Han, Wenchao Liu, Yang Zhang, Huimin Wang, Xian-qiao Jin, Liyan Jiang, Zhixiang Zhuang, Yi Luo, Aiqin Gu, Jianying Zhou, Qing-yu Xiu
Publikováno v: Journal of Thoracic Oncology. (6):1104-1109
Introduction: Recombinant human endostatin is a novel inhibitor of tumor angiogenesis that acts specifically on neovascular endothelial cells. Studies have shown that endostar plus vinorelbine-cisplatin chemotherapy could improve objective response r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2f6aa0670a1465f88c56327f2d32a6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje